What is Bipolar Androgen Therapy and how does it work

Understanding Bipolar Androgen Therapy (BAT)

Bipolar Androgen Therapy is an innovative treatment approach for advanced prostate cancer, particularly for men whose cancer has become resistant to standard hormone therapy. Let me explain how it works and why it's called "bipolar."

What Makes It "Bipolar"?

The term "bipolar" refers to the two opposite extremes of testosterone levels that the therapy cycles through:

Phase 1: High Testosterone (Supraphysiological)

• Testosterone levels are raised to very high levels—much higher than normal in the body (greater than 1,500 ng/dL)
• This is typically done with monthly injections of 400 mg of testosterone cypionate
• This phase lasts about 2-4 weeks

Phase 2: Low Testosterone (Castrate Level)

• Testosterone is then driven down to very low levels (less than 150 ng/dL)
• This mimics the effect of standard androgen deprivation therapy (ADT)—the hormone-blocking drugs like Lupron or Eligard
• This phase lasts several weeks before cycling back to high levels

How Does BAT Actually Work?

According to expert discussions in the CancerPatientLab webinars on BAT, the therapy works through several mechanisms:

The DNA Damage Strategy: When testosterone levels spike to supraphysiological levels, this creates DNA double-strand breaks in cancer cells—essentially damaging the cancer cells' genetic material. If these breaks aren't repaired, the cancer cells may die (undergo apoptosis) or enter a dormant state (senescence).

Exploiting Cancer Cell Weakness: Prostate cancer cells that have become resistant to standard hormone therapy often have upregulated androgen receptors—think of these as "locks" on the cell surface that need testosterone (the "key") to function. When you suddenly flood the system with high testosterone, these cells are forced to proliferate (grow and divide) rapidly. This rapid growth under stress conditions can trigger cell death.

Resensitizing Resistant Cancer: One of BAT's most important benefits is that it can potentially convert castrate-resistant prostate cancer (CRPC)—cancer that no longer responds to hormone therapy—back into hormone-sensitive cancer. According to the CancerPatientLab webinars, in the TRANSFORMER study, 78% of men had a response to the drug Xtandi (enzalutamide) after BAT was performed first, compared to the conventional response rate of about 26%.

Response Patterns

According to Emmanuel Antonarakis's expert webinar on BAT, responses tend to divide into thirds:

• One-third see marked improvement in PSA levels and cancer reduction
• One-third see PSA plateau (no progression—which is still a benefit)
• One-third see PSA increase and continued cancer growth

Important note: PSA (prostate-specific antigen) is an imperfect marker. Sometimes PSA increases while scans show no growth or even regression. Your doctor will monitor you with PSA tests, imaging scans, and clinical symptoms.

Who Might Be a Good Candidate?

BAT may be considered when:

• You're becoming castrate-resistant (your PSA rises despite hormone therapy)
• You've already tried standard hormone therapies
• You have certain genetic mutations associated with better BAT response (such as BRCA2, TP53, or other DNA repair gene mutations)

According to the webinars, men with homologous recombination repair (HRR) mutations had a 68% PSA response rate, compared to 37% in men without these mutations.

Important Limitations

BAT is not recommended if you have:

• Symptomatic bone pain (BAT could worsen it)
• Bone metastases near the spine or threatening fracture
• A bulky prostate or enlarged lymph nodes that could obstruct your urinary tract

Quality of Life Benefits

Beyond cancer control, the CancerPatientLab webinars note that BAT often improves quality of life, particularly regarding libido and energy levels—improvements that standard continuous hormone therapy doesn't typically provide.

Questions to Ask Your Oncologist

If BAT is being discussed for your care:

1. Am I a candidate for BAT based on my specific cancer characteristics and treatment history?
2. What genetic testing would help predict if I might respond well to BAT?
3. How would you monitor my response—what tests and how often?
4. What are the potential side effects I should expect during the high and low testosterone phases?
5. If BAT is successful, what would the long-term treatment plan look like?

---

Sources Referenced:

• NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer (2024)
• CancerPatientLab Webinars: "Bipolar Androgen Therapy for Prostate Cancer" (Emmanuel Antonarakis)
• CancerPatientLab Webinars: "Bipolar Androgen Therapy" (Bryce Olson and Bob Gatenby)
• CancerPatientLab Webinars: "How I Am Running Experiments on Myself to Control My Prostate Cancer – Using Bipolar Androgen Therapy" (Russ Hollyer)

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.